Recent

% | $
Quotes you view appear here for quick access.

Delcath Systems, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • toolatetrade toolatetrade May 17, 2004 6:39 PM Flag

    10QSB Troubles???

    the question is do the patients get a life extention from this treatment, not just tumor sinkage. no life extention may result in FDA denial. again, anyone have info on this????

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Surgery is ususally the only chance for survival when it comes to liver cancer. By the time liver cancer is detected the tumor is to big to be operated on. So the fact that Delcath, in the past, has shown sig tumor shrinkage is important because these patients will become operative canditates.

      If we see increase life extention, it will be most likely because of tumor shrinkage that gives a surgeon the chance to remove the rest of the tumor.

      Koly mention in the CEO cast interview that one of their patients lived for 5 years. But since phase I and II studies usually involved a small number of patients and no control, this is not stag-sig data.

      Also, They had 1 patient in the Phase II (I believe) that the the tumor disapeared for 10 months...

      Look past on this board, their are many posts that point out these facts...

 
DCTH
2.47-0.98(-28.26%)Sep 30 3:59 PMEDT